about
Aneuploidy and drug resistance in pathogenic fungiDeletion of Cryptococcus neoformans AIF ortholog promotes chromosome aneuploidy and fluconazole-resistance in a metacaspase-independent mannerCharacterization of the chromosome 4 genes that affect fluconazole-induced disomy formation in Cryptococcus neoformansAntifungal drug susceptibility and phylogenetic diversity among Cryptococcus isolates from dogs and cats in North America.Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis.A low-affinity penicillin-binding protein 2x variant is required for heteroresistance in Streptococcus pneumoniae.High-dose fluconazole in combination with amphotericin B is more efficient than monotherapy in murine model of cryptococcosis.Variation in chromosome copy number influences the virulence of Cryptococcus neoformans and occurs in isolates from AIDS patients.Regulatory circuitry governing fungal development, drug resistance, and disease.Genome variation in Cryptococcus gattii, an emerging pathogen of immunocompetent hosts.The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug.Microbiological, epidemiological, and clinical characteristics and outcomes of patients with cryptococcosis in Taiwan, 1997-2010Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole.Heteroresistance to Itraconazole Alters the Morphology and Increases the Virulence of Cryptococcus gattii.Cryptococcus neoformans Yop1 , an endoplasmic reticulum curvature-stabilizing protein, participates with Sey1 in influencing fluconazole-induced disomy formationCryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.Identification of antifungal natural products via Saccharomyces cerevisiae bioassay: insights into macrotetrolide drug spectrum, potency and mode of action.Azole heteroresistance in Cryptococcus neoformans: emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatmentExpanding fungal pathogenesis: Cryptococcus breaks out of the opportunistic box.Opportunistic fungal infections in the Asia-Pacific region.Cryptococcus gattii comparative genomics and transcriptomics: a NIH/NIAID White Paper.Fluconazole resistance in cryptococcal disease: emerging or intrinsic?Cryptococcosis as an emerging systemic mycosis in dogs.Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment.Impact of Resistance to Fluconazole on Virulence and Morphological Aspects of Cryptococcus neoformans and Cryptococcus gattii Isolates.The fungal resistome: a risk and an opportunity for the development of novel antifungal therapies.Synthesis and antifungal activity in vitro of isoniazid derivatives against histoplasma capsulatum var. capsulatum.Molecular typing of environmental Cryptococcus neoformans/C. gattii species complex isolates from Manaus, Amazonas, Brazil.Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.Ploidy dynamics and evolvability in fungiHeteroresistance and fungi.Review of some pharmacokinetic and pharmacodynamic properties of anti-infective medicines administered to the koala (Phascolarctos cinereus).Central nervous system infection due to Cryptococcus gattii sensu lato in India: Analysis of clinical features, molecular profile and antifungal susceptibility.In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations.Diversity and Antifungal Drug Susceptibility of Cryptococcus Isolates in Thailand.Molecular identification, antifungal resistance and virulence of Cryptococcus neoformans and Cryptococcus deneoformans isolated in Seville, Spain.In vivo development of fluconazole resistance in serial Cryptococcus gattii isolates from a cat.Some pharmacokinetic indices of oral fluconazole administration to koalas (Phascolarctos cinereus) infected with cryptococcosis.A case report of pulmonary cryptococcosis presenting as endobronchial obstruction.Rare Cryptococus gattii infection in an immunocompetent dairy goat following a cesarean section
P2860
Q27011632-04919F29-A6C0-4540-881C-3B1711B7AD05Q28478069-1EF7CBC7-B333-4A4A-B3FB-15212B0B6336Q28481426-39AA2677-02AA-4582-B64E-3ABDE97DF373Q33703525-93B2DC6E-A6D1-46A5-8D3C-1F92D2EB31ECQ33790656-C151EDDE-3E76-4A10-A3E2-08D5E56E8857Q33798560-1FC1D0F6-C733-49CA-883F-38C0FE195136Q33875911-B9B9EF5A-C42D-4D62-8A3B-FFF2BA22AF86Q34059795-B2309DA1-8B09-4116-B365-7296759ACB34Q34190284-ED0A584C-203F-4A3C-9D49-4AF28E7B2FEFQ34565901-45F15B1C-C9A8-41F9-B4C0-2D93C586858CQ34596780-BCCD0FBC-A0EB-4D5B-BD03-71B1D6CB12A6Q34685419-0C996E20-58FF-469B-8669-FCA8366A2B46Q35806201-915E757F-ED33-47D1-B546-F855CB8A086BQ35860071-1F75B8E8-02D8-45A8-AC29-DC85CD58B0D9Q36319731-0A150AD6-D9FC-45C8-A583-EEC50103A6D2Q36364064-9C9B0CF1-6428-4A8E-A7CC-5FF97637A3F5Q36674558-191D71F3-684F-4D48-898A-1F8DCE8A4F4AQ37263749-D0288F10-0DEA-427A-896A-5FBAE24BE31AQ37843446-436F56C4-BB8F-4263-B105-2400B1733616Q37929788-E9DBA211-8606-4799-83C0-011F38D840EAQ37969662-C2FBFE33-CFD7-41B5-BA86-5B212838D2D3Q38044487-BB26F67F-99F7-43BC-A31B-112EF60601D1Q38131855-B9DD154E-9CAD-40BE-8D3D-07A2260AE3B4Q38154164-783A443D-1879-48FE-9954-0AE9D5EC10E2Q38467366-25F2576C-5628-4A3B-9E0C-8E4D0256DD4EQ38835045-E0C0B88D-7B9F-45F6-A861-5A3164704335Q38848844-6AB5E083-EA71-4806-8E21-9C31B8A33F63Q38871468-15F40570-7C81-4851-A158-B2CA8C7055E1Q39064815-B2DF4319-F3EB-4BBF-B2BB-DF44AC8E68C2Q39084067-027745AC-341D-49D8-84EF-4AF70AE183FCQ39404146-AB2612CD-E46F-4972-A0D7-6C5648B3564AQ39432406-DBD3215E-15BA-4F97-BE1E-442EE85ED868Q40111169-9F0A5EC6-4E97-4F42-A995-69FD91467D5DQ40325403-157C5DC5-CEB6-45D4-BE15-2FBEC252A299Q40424785-720A9A20-4BD7-40F7-B637-31993CAE04C6Q40538476-0120D770-D86A-4CFF-9D3F-32432C001166Q40851096-AA956B58-5F6F-444E-A5C3-2551F7D3B4B6Q40871509-68E54DBA-3C0E-4B63-9316-507DCEA1F786Q42574926-237C2490-0FF3-447B-BA98-9A0680B760ECQ42838577-ABBC8DD5-825B-4C73-9D4E-418464A43FBD
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Heteroresistance of Cryptococcus gattii to fluconazole.
@ast
Heteroresistance of Cryptococcus gattii to fluconazole.
@en
type
label
Heteroresistance of Cryptococcus gattii to fluconazole.
@ast
Heteroresistance of Cryptococcus gattii to fluconazole.
@en
prefLabel
Heteroresistance of Cryptococcus gattii to fluconazole.
@ast
Heteroresistance of Cryptococcus gattii to fluconazole.
@en
P2860
P356
P1476
Heteroresistance of Cryptococcus gattii to fluconazole.
@en
P2093
K J Kwon-Chung
P2860
P304
P356
10.1128/AAC.00153-10
P407
P577
2010-04-12T00:00:00Z